查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球支气管扩张剂市场规模、份额、行业趋势分析报告：按药物类别、给药途径、疾病（哮喘、慢性阻塞性肺病 (COPD) 等）地区展望和预测2022-2028
市场调查报告书
商品编码
1219629

全球支气管扩张剂市场规模、份额、行业趋势分析报告：按药物类别、给药途径、疾病（哮喘、慢性阻塞性肺病 (COPD) 等）地区展望和预测2022-2028

Global Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 203 Pages | 订单完成后即时交付

价格

在预测期内，支气管扩张剂的全球市场规模预计将以 3.9% 的复合年增长率增长，到 2028 年将达到 270 亿美元。

BETA 2 激动剂可用于 COPD 和哮喘，但某些 BETA 2 激动剂仅推荐用于 COPD 患者。 它通常在小型手持吸入器的帮助下吸入，但也以糖浆或药片的形式出售。 如果症状突然或严重，可以将药物注射到体内或使用雾化器。 雾化器是一种压缩机，可将药液变成细雾。 Beta-2 激动剂通过刺激气道肌肉中称为 beta-2 受体的受体起作用，导致肌肉放鬆和气道扩张。

抗胆碱能药物也称为抗毒蕈碱药物，主要用于治疗慢性阻塞性肺病，但在某些情况下也用于治疗哮喘。 它们是在吸入器的帮助下服用的，但在突然需要时可以使用雾化药物。 抗胆碱药通过阻断胆碱能神经来扩张气道。 这些神经会释放化学物质，迫使气道内壁的肌肉收紧。 茶碱通常以胶囊或药片的形式服用，但如果症状严重，可以直接静脉注射另一种叫做氨茶碱的药物。

COVID-19 影响分析

COVID-19 对支气管扩张剂市场产生了早期影响，因为许多国家由于对 COPD 和哮喘患者的重视而拒□□绝治疗并锁定 COPD 和哮喘患者。 由于供应链中断，支气管扩张剂短缺。 由于大流行和劳动力短缺，许多支气管扩张剂製造商被迫停产。 此外，新的政府法规已经停止了商业活动，直接影响了公司在支气管扩张剂市场的收益。

市场增长因素

全球空气污染加剧

汽车、家庭燃烧、森林火灾和工业设施是空气污染的常见来源。 主要公共卫生问题的污染物包括颗粒物、一氧化碳、臭氧、二氧化硫和氮气。 室内和室外空气污染是死亡率和发病率的主要原因，会引起呼吸系统疾病等。 根据世界卫生组织 (WHO) 的数据，世界上几乎每个人都呼吸着超过 WHO 指南规定的限度的污染空气。 其中，低收入和中等收入国家的风险最高。

老年人口增加

据世界卫生组织称，到 2030 年，世界上六分之一的人将超过 60 岁。 全球 60 岁及以上人口的比例将从 2020 年的 10 亿增加到 14 亿。 2020 年至 2050 年间，全球 60 岁及以上的人口将翻一番，达到约 21 亿，而 80 岁的人口将增加两倍，达到 4.26 亿。 一个国家的人口分布向老年人的转变，即人口老龄化，在高收入国家已经开始，但目前在低收入和中等收入国家正在发生最大的变化。 到 2050 年，世界上三分之二的人口将在低收入和中等收入国家超过 60 岁。

市场製约因素

影像诊断设备成本高

胸部 X 光检查可以帮助诊断许多肺部疾病并排除导致呼吸急促的其他原因。 发展中国家的各种医院由于成本高和财政拮据而无力投资诊断影像设备。 由于对诊断的高需求，特别是在低收入国家，许多买不起最新成像设备的医院选择使用重建的成像设备。

药物类别展望

支气管扩张剂市场按药物类别分为 BETA-肾上腺素能药物、黄嘌呤衍生物和抗胆碱能药物。 2021 年，抗胆碱能药物在支气管扩张剂市场取得了令人鼓舞的增长率。 这是由于短效和长效製剂中抗胆碱能药的可用性。 这些药物可以防止副交感神经反射收缩气道，保持气道畅通。

管理路线展望

支气管扩张剂市场按给药途径分为口服、鼻腔（吸入）和注射剂型。 2021 年，口服部分在支气管扩张剂市场中占据了显着的收入份额。 这是因为许多患者和临床医生更愿意避免注射给药的副作用。 它还具有许多优势，包括比许多通用替代品成本更低、非侵入性、给药方便和患者依从性。

疾病前景

支气管扩张剂市场按疾病分为哮喘、慢性阻塞性肺病 (COPD) 等。 2021 年，哮喘细分市场在支气管扩张剂市场的收入份额最大。 这是由于人口中哮喘患病率上升。 此外，中后期开发机构众多，研发管线充实。

区域展望

按地区划分，对北美、欧洲、亚太地区和 LAMEA 的支气管扩张剂市场进行了分析。 北美地区将在 2021 年占据支气管扩张剂市场的最高收入份额。 这种增长是由对速效和高效药物不断增长的需求推动的。 慢性阻塞性肺病病例的激增是由于空气污染、灰尘、接触化学品、先前存在的儿童肺部感染和被动吸烟。 这也是由于吸烟者人数众多。 空气污染、吸烟者人数众多、老年人口增加等预计将推动该地区支气管扩张剂市场的增长。

内容

第一章市场范围与研究方法

  • 市场定义
  • 目的
  • 市场规模
  • 细分
    • 全球支气管扩张剂市场，按药物类别
    • 全球支气管扩张剂市场，按给药途径
    • 全球支气管扩张剂市场，按疾病分类
    • 全球支气管扩张剂市场，按地区
  • 调查方法

第 2 章市场概述

  • 介绍
    • 概览
      • 市场构成和情景
  • 影响市场的主要因素
    • 市场驱动力
    • 市场製约因素

第 3 章全球支气管扩张剂市场：按药物类别分类

  • 全球 BETA-肾上腺素市场，按地区
  • 按地区划分的黄嘌呤衍生物的世界市场
  • 全球抗胆碱药市场：按地区

第 4 章支气管扩张剂的全球市场：按给药途径分类

  • 全球鼻腔（吸入）市场：按地区
  • 全球口服药市场：按地区
  • 全球注射剂市场，按地区划分

第 5 章全球支气管扩张剂市场：按疾病分类

  • 全球哮喘市场：按地区
  • 全球慢性阻塞性肺病 (COPD) 市场：按地区
  • 世界其他地区市场：按地区

第 6 章全球支气管扩张剂市场：按地区划分的区域市场

  • 北美
    • 北美支气管扩张剂市场：按国家/地区细分
      • 美国
      • 加拿大
      • 墨西哥
      • 其他北美地区
  • 欧洲
    • 按国家/地区划分的欧洲支气管扩张剂市场
      • 德国
      • 英国
      • 法国
      • 俄罗斯
      • 西班牙
      • 意大利
      • 其他欧洲
  • 亚太地区
    • 按国家/地区划分的亚太地区支气管扩张剂市场
      • 中国
      • 日本
      • 印度
      • 韩国
      • 新加坡
      • 马来西亚
      • 其他亚太地区
  • 拉美
    • LAMEA 支气管扩张剂市场：按国家/地区分类
      • 巴西
      • 阿根廷
      • 阿联酋
      • 沙特阿拉伯
      • 南非
      • 尼日利亚
      • 其他拉美地区

第七章公司简介

  • Glenmark Pharmaceuticals Limited
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Viatris, Inc.（Mylan N.V.）
  • Novartis AG
  • Boehringer Ingelheim International Gmbh
  • Sun Pharmaceutical Industries Ltd.

The Global Bronchodilators Market size is expected to reach $27 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.

Bronchodilators are drugs that relax the muscles which tighten around the airways. These drugs open airways and allow more air to come and pass through the lungs and decrease mucus from the lungs. Patients suffering from various respiratory disorders take these drugs through nebulizers or inhalers. Also, inhaling bronchodilators have effects on mucociliary clearance too.

Bronchodilators are also utilized to treat obstructive lung diseases by relaxing the muscles in the lungs and widening the airways (bronchi). They also treat chronic obstructive pulmonary diseases (COPD) and asthma. The relaxation of the muscles in the airways due to the bronchodilators, opens them up and the bronchial tube to widen. They come in different types and each works in a slightly different way than the other. They are; beta 2-agonists, anticholinergics and xanthine derivatives (theophylline).

Beta-2 agonists are utilized for both COPD and asthma, but some beta-2 agonists are only recommended for patients with COPD. They are generally inhaled with the help of a small handheld inhaler but are available as syrups or tablets too. In case of sudden or severe symptoms, they can also be injected into the body or nebulized. A nebulizer is a compressor that changes the liquid medication into a fine mist. Beta-2 agonists work by stimulating receptors known as beta-2 receptors in the muscles that are in the airways, which causes them to relax and allow the airways to dilate.

Anticholinergics, also known as antimuscarinics, are majorly used for treating COPD, but in some cases, they can also be used to treat asthma. They are taken with the help of an inhaler, but nebulizing the medication is also available for sudden need. Anticholinergics cause the airway to dilate by blocking the cholinergic nerves. These nerves release a chemical that can force the muscles lining the airways to tighten up. Theophylline is generally taken in capsule or tablet form, but a different version called aminophylline can be given directly into the vein if the symptoms are severe.

COVID-19 Impact Analysis

COVID-19 has impacted the bronchodilators market in the starting phase due to the lockdowns by many nations with the denied COPD and asthma treatment due to the given importance to COVID-19 patients. Because of the halt in the supply chain, there was a shortage of bronchodilator medications. Many bronchodilators manufacturing companies were forced to stop their production due to the pandemic and labor shortage. Furthermore, business operations were halted due to the new government regulations, which directly influenced the companies' revenue in the bronchodilators market.

Market Growth Factor

Increasing air pollution across the globe

Motor vehicles, household combustion, forest fires, and industrial facilities are familiar air pollution sources. Pollutants of primary public health concern contain particulate matter, carbon monoxide, ozone, sulfur dioxide, and nitrogen. Indoor and outdoor air pollution cause respiratory and other diseases and are significant factors for mortality and morbidity. According to World Health Organization, almost all of the world's population breathes air that exceeds WHO guideline limits and has high levels of pollutants. Out of that, low and middle-income countries are suffering from the highest exposures.

Surging number of geriatric populations

According to WHO, one in every six people in the world will be aged 60 years or over by 2030. The share of the world's population aged 60 years and above will rise from 1 billion in 2020 to 1.4 billion. The world's population of people aged 60 years and older will double to around 2.1 billion, and the 80 years old will triple to 426 million between 2020 and 2050. While this shift in the distribution of a country's population towards the older ages, called population aging, has already started in high-income nations, it is now experiencing the most significant change in low- and middle-income countries. By 2050, two-thirds of the world's population will be over 60 years old and in low- or middle-income countries.

Market Restraining Factor

High cost of imaging equipment

A chest X-ray can aid in assisting the diagnosis of many lung diseases and rule out other causes of shortness of breath. Various hospitals in developing nations cannot invest in diagnostic imaging equipment due to high costs and financial restrictions. Many hospitals that cannot buy new cutting-edge imaging systems instead opt to utilize rebuilt imaging systems because of the high demand for diagnostics procedures, especially in low-income countries.

Drug Class Outlook

Based on drug class, the bronchodilators market is segmented into beta-adrenergic, xanthine derivatives and anticholinergic. The anticholinergic segment acquired a promising growth rate in the bronchodilators market in 2021. This is due to anticholinergics' availability in short- and long-acting formulations. These drugs prevent the parasympathetic nerve reflexes from airways constriction, which allows the airways to remain open.

Route of Administration Outlook

On the basis of route of administration, the bronchodilators market is divided into oral, nasal (inhalable) and injectable. The oral segment procured a prominent revenue share in the bronchodilator market in 2021. This is because many patients and clinicians prefer to avoid the adverse effects of injectables administration. Also, they are less costly than many generic substitutes and have many advantages like non-invasiveness, the convenience of drug administration, and patient compliance.

Disease Outlook

By disease, the bronchodilators market is classified into asthma, chronic obstructive pulmonary disease (COPD) and others. The asthma segment witnessed the largest revenue share in the bronchodilator market in 2021. This is due to the rising prevalence of asthma among the population. In addition, there is a robust research and development pipeline with many mid or late-stage development organizations.

Regional Outlook

Region-wise, the bronchodilators market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the bronchodilator market in 2021. The growth is due to the increasing demand for fast-acting and high-efficiency drugs. The surging COPD cases are due to air pollution, dust, working with chemicals, a history of childhood lung infection, and second-hand smoke. Also, there is a large number of smokers who are suffering from a smoke-related disease. The air pollution, high smoker count, and the rising number of old adults are expected to boost the bronchodilators market growth in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Beta-Adrenergic
  • Xanthine Derivatives
  • Anticholinergic

By Route of Administration

  • Nasal (Inhalable)
  • Oral
  • Injectable

By Disease

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Glenmark Pharmaceuticals Limited
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Cipla Limited
  • Viatris, Inc.
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Bronchodilators Market, by Drug Class
    • 1.4.2 Global Bronchodilators Market, by Route of Administration
    • 1.4.3 Global Bronchodilators Market, by Disease
    • 1.4.4 Global Bronchodilators Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Bronchodilators Market by Drug Class

  • 3.1 Global Beta-Adrenergic Market by Region
  • 3.2 Global Xanthine Derivatives Market by Region
  • 3.3 Global Anticholinergic Market by Region

Chapter 4. Global Bronchodilators Market by Route of Administration

  • 4.1 Global Nasal (Inhalable) Market by Region
  • 4.2 Global Oral Market by Region
  • 4.3 Global Injectable Market by Region

Chapter 5. Global Bronchodilators Market by Disease

  • 5.1 Global Asthma Market by Region
  • 5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region
  • 5.3 Global Others Market by Region

Chapter 6. Global Bronchodilators Market by Region

  • 6.1 North America Bronchodilators Market
    • 6.1.1 North America Bronchodilators Market by Drug Class
      • 6.1.1.1 North America Beta-Adrenergic Market by Country
      • 6.1.1.2 North America Xanthine Derivatives Market by Country
      • 6.1.1.3 North America Anticholinergic Market by Country
    • 6.1.2 North America Bronchodilators Market by Route of Administration
      • 6.1.2.1 North America Nasal (Inhalable) Market by Country
      • 6.1.2.2 North America Oral Market by Country
      • 6.1.2.3 North America Injectable Market by Country
    • 6.1.3 North America Bronchodilators Market by Disease
      • 6.1.3.1 North America Asthma Market by Country
      • 6.1.3.2 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.1.3.3 North America Others Market by Country
    • 6.1.4 North America Bronchodilators Market by Country
      • 6.1.4.1 US Bronchodilators Market
        • 6.1.4.1.1 US Bronchodilators Market by Drug Class
        • 6.1.4.1.2 US Bronchodilators Market by Route of Administration
        • 6.1.4.1.3 US Bronchodilators Market by Disease
      • 6.1.4.2 Canada Bronchodilators Market
        • 6.1.4.2.1 Canada Bronchodilators Market by Drug Class
        • 6.1.4.2.2 Canada Bronchodilators Market by Route of Administration
        • 6.1.4.2.3 Canada Bronchodilators Market by Disease
      • 6.1.4.3 Mexico Bronchodilators Market
        • 6.1.4.3.1 Mexico Bronchodilators Market by Drug Class
        • 6.1.4.3.2 Mexico Bronchodilators Market by Route of Administration
        • 6.1.4.3.3 Mexico Bronchodilators Market by Disease
      • 6.1.4.4 Rest of North America Bronchodilators Market
        • 6.1.4.4.1 Rest of North America Bronchodilators Market by Drug Class
        • 6.1.4.4.2 Rest of North America Bronchodilators Market by Route of Administration
        • 6.1.4.4.3 Rest of North America Bronchodilators Market by Disease
  • 6.2 Europe Bronchodilators Market
    • 6.2.1 Europe Bronchodilators Market by Drug Class
      • 6.2.1.1 Europe Beta-Adrenergic Market by Country
      • 6.2.1.2 Europe Xanthine Derivatives Market by Country
      • 6.2.1.3 Europe Anticholinergic Market by Country
    • 6.2.2 Europe Bronchodilators Market by Route of Administration
      • 6.2.2.1 Europe Nasal (Inhalable) Market by Country
      • 6.2.2.2 Europe Oral Market by Country
      • 6.2.2.3 Europe Injectable Market by Country
    • 6.2.3 Europe Bronchodilators Market by Disease
      • 6.2.3.1 Europe Asthma Market by Country
      • 6.2.3.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.2.3.3 Europe Others Market by Country
    • 6.2.4 Europe Bronchodilators Market by Country
      • 6.2.4.1 Germany Bronchodilators Market
        • 6.2.4.1.1 Germany Bronchodilators Market by Drug Class
        • 6.2.4.1.2 Germany Bronchodilators Market by Route of Administration
        • 6.2.4.1.3 Germany Bronchodilators Market by Disease
      • 6.2.4.2 UK Bronchodilators Market
        • 6.2.4.2.1 UK Bronchodilators Market by Drug Class
        • 6.2.4.2.2 UK Bronchodilators Market by Route of Administration
        • 6.2.4.2.3 UK Bronchodilators Market by Disease
      • 6.2.4.3 France Bronchodilators Market
        • 6.2.4.3.1 France Bronchodilators Market by Drug Class
        • 6.2.4.3.2 France Bronchodilators Market by Route of Administration
        • 6.2.4.3.3 France Bronchodilators Market by Disease
      • 6.2.4.4 Russia Bronchodilators Market
        • 6.2.4.4.1 Russia Bronchodilators Market by Drug Class
        • 6.2.4.4.2 Russia Bronchodilators Market by Route of Administration
        • 6.2.4.4.3 Russia Bronchodilators Market by Disease
      • 6.2.4.5 Spain Bronchodilators Market
        • 6.2.4.5.1 Spain Bronchodilators Market by Drug Class
        • 6.2.4.5.2 Spain Bronchodilators Market by Route of Administration
        • 6.2.4.5.3 Spain Bronchodilators Market by Disease
      • 6.2.4.6 Italy Bronchodilators Market
        • 6.2.4.6.1 Italy Bronchodilators Market by Drug Class
        • 6.2.4.6.2 Italy Bronchodilators Market by Route of Administration
        • 6.2.4.6.3 Italy Bronchodilators Market by Disease
      • 6.2.4.7 Rest of Europe Bronchodilators Market
        • 6.2.4.7.1 Rest of Europe Bronchodilators Market by Drug Class
        • 6.2.4.7.2 Rest of Europe Bronchodilators Market by Route of Administration
        • 6.2.4.7.3 Rest of Europe Bronchodilators Market by Disease
  • 6.3 Asia Pacific Bronchodilators Market
    • 6.3.1 Asia Pacific Bronchodilators Market by Drug Class
      • 6.3.1.1 Asia Pacific Beta-Adrenergic Market by Country
      • 6.3.1.2 Asia Pacific Xanthine Derivatives Market by Country
      • 6.3.1.3 Asia Pacific Anticholinergic Market by Country
    • 6.3.2 Asia Pacific Bronchodilators Market by Route of Administration
      • 6.3.2.1 Asia Pacific Nasal (Inhalable) Market by Country
      • 6.3.2.2 Asia Pacific Oral Market by Country
      • 6.3.2.3 Asia Pacific Injectable Market by Country
    • 6.3.3 Asia Pacific Bronchodilators Market by Disease
      • 6.3.3.1 Asia Pacific Asthma Market by Country
      • 6.3.3.2 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.3.3.3 Asia Pacific Others Market by Country
    • 6.3.4 Asia Pacific Bronchodilators Market by Country
      • 6.3.4.1 China Bronchodilators Market
        • 6.3.4.1.1 China Bronchodilators Market by Drug Class
        • 6.3.4.1.2 China Bronchodilators Market by Route of Administration
        • 6.3.4.1.3 China Bronchodilators Market by Disease
      • 6.3.4.2 Japan Bronchodilators Market
        • 6.3.4.2.1 Japan Bronchodilators Market by Drug Class
        • 6.3.4.2.2 Japan Bronchodilators Market by Route of Administration
        • 6.3.4.2.3 Japan Bronchodilators Market by Disease
      • 6.3.4.3 India Bronchodilators Market
        • 6.3.4.3.1 India Bronchodilators Market by Drug Class
        • 6.3.4.3.2 India Bronchodilators Market by Route of Administration
        • 6.3.4.3.3 India Bronchodilators Market by Disease
      • 6.3.4.4 South Korea Bronchodilators Market
        • 6.3.4.4.1 South Korea Bronchodilators Market by Drug Class
        • 6.3.4.4.2 South Korea Bronchodilators Market by Route of Administration
        • 6.3.4.4.3 South Korea Bronchodilators Market by Disease
      • 6.3.4.5 Singapore Bronchodilators Market
        • 6.3.4.5.1 Singapore Bronchodilators Market by Drug Class
        • 6.3.4.5.2 Singapore Bronchodilators Market by Route of Administration
        • 6.3.4.5.3 Singapore Bronchodilators Market by Disease
      • 6.3.4.6 Malaysia Bronchodilators Market
        • 6.3.4.6.1 Malaysia Bronchodilators Market by Drug Class
        • 6.3.4.6.2 Malaysia Bronchodilators Market by Route of Administration
        • 6.3.4.6.3 Malaysia Bronchodilators Market by Disease
      • 6.3.4.7 Rest of Asia Pacific Bronchodilators Market
        • 6.3.4.7.1 Rest of Asia Pacific Bronchodilators Market by Drug Class
        • 6.3.4.7.2 Rest of Asia Pacific Bronchodilators Market by Route of Administration
        • 6.3.4.7.3 Rest of Asia Pacific Bronchodilators Market by Disease
  • 6.4 LAMEA Bronchodilators Market
    • 6.4.1 LAMEA Bronchodilators Market by Drug Class
      • 6.4.1.1 LAMEA Beta-Adrenergic Market by Country
      • 6.4.1.2 LAMEA Xanthine Derivatives Market by Country
      • 6.4.1.3 LAMEA Anticholinergic Market by Country
    • 6.4.2 LAMEA Bronchodilators Market by Route of Administration
      • 6.4.2.1 LAMEA Nasal (Inhalable) Market by Country
      • 6.4.2.2 LAMEA Oral Market by Country
      • 6.4.2.3 LAMEA Injectable Market by Country
    • 6.4.3 LAMEA Bronchodilators Market by Disease
      • 6.4.3.1 LAMEA Asthma Market by Country
      • 6.4.3.2 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.4.3.3 LAMEA Others Market by Country
    • 6.4.4 LAMEA Bronchodilators Market by Country
      • 6.4.4.1 Brazil Bronchodilators Market
        • 6.4.4.1.1 Brazil Bronchodilators Market by Drug Class
        • 6.4.4.1.2 Brazil Bronchodilators Market by Route of Administration
        • 6.4.4.1.3 Brazil Bronchodilators Market by Disease
      • 6.4.4.2 Argentina Bronchodilators Market
        • 6.4.4.2.1 Argentina Bronchodilators Market by Drug Class
        • 6.4.4.2.2 Argentina Bronchodilators Market by Route of Administration
        • 6.4.4.2.3 Argentina Bronchodilators Market by Disease
      • 6.4.4.3 UAE Bronchodilators Market
        • 6.4.4.3.1 UAE Bronchodilators Market by Drug Class
        • 6.4.4.3.2 UAE Bronchodilators Market by Route of Administration
        • 6.4.4.3.3 UAE Bronchodilators Market by Disease
      • 6.4.4.4 Saudi Arabia Bronchodilators Market
        • 6.4.4.4.1 Saudi Arabia Bronchodilators Market by Drug Class
        • 6.4.4.4.2 Saudi Arabia Bronchodilators Market by Route of Administration
        • 6.4.4.4.3 Saudi Arabia Bronchodilators Market by Disease
      • 6.4.4.5 South Africa Bronchodilators Market
        • 6.4.4.5.1 South Africa Bronchodilators Market by Drug Class
        • 6.4.4.5.2 South Africa Bronchodilators Market by Route of Administration
        • 6.4.4.5.3 South Africa Bronchodilators Market by Disease
      • 6.4.4.6 Nigeria Bronchodilators Market
        • 6.4.4.6.1 Nigeria Bronchodilators Market by Drug Class
        • 6.4.4.6.2 Nigeria Bronchodilators Market by Route of Administration
        • 6.4.4.6.3 Nigeria Bronchodilators Market by Disease
      • 6.4.4.7 Rest of LAMEA Bronchodilators Market
        • 6.4.4.7.1 Rest of LAMEA Bronchodilators Market by Drug Class
        • 6.4.4.7.2 Rest of LAMEA Bronchodilators Market by Route of Administration
        • 6.4.4.7.3 Rest of LAMEA Bronchodilators Market by Disease

Chapter 7. Company Profiles

  • 7.1 Glenmark Pharmaceuticals Limited
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Research & Development Expenses
    • 7.1.4 Recent strategies and developments:
      • 7.1.4.1 Product Launches and Product Expansions:
  • 7.2 Merck & Co., Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 GlaxoSmithKline PLC
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expense
  • 7.4 AstraZeneca PLC
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Regional Analysis
    • 7.4.4 Research & Development Expenses
  • 7.5 Teva Pharmaceutical Industries Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Regional Analysis
    • 7.5.4 Research & Development Expenses
  • 7.6 Cipla Limited
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expense
  • 7.7 Viatris, Inc. (Mylan N.V.)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Boehringer Ingelheim International Gmbh
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Regional & Segmental Analysis
    • 7.9.4 Research & Development Expenses
  • 7.10. Sun Pharmaceutical Industries Ltd.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Regional & Segmental Analysis
    • 7.10.4 Research & Development Expenses

LIST OF TABLES

  • TABLE 1 Global Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 2 Global Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 3 Global Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 4 Global Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 5 Global Beta-Adrenergic Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Beta-Adrenergic Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Xanthine Derivatives Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Xanthine Derivatives Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Anticholinergic Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global Anticholinergic Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 12 Global Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 13 Global Nasal (Inhalable) Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Nasal (Inhalable) Market by Region, 2022 - 2028, USD Million
  • TABLE 15 Global Oral Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Oral Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Injectable Market by Region, 2018 - 2021, USD Million
  • TABLE 18 Global Injectable Market by Region, 2022 - 2028, USD Million
  • TABLE 19 Global Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 20 Global Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 21 Global Asthma Market by Region, 2018 - 2021, USD Million
  • TABLE 22 Global Asthma Market by Region, 2022 - 2028, USD Million
  • TABLE 23 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region, 2018 - 2021, USD Million
  • TABLE 24 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region, 2022 - 2028, USD Million
  • TABLE 25 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 26 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 27 Global Bronchodilators Market by Region, 2018 - 2021, USD Million
  • TABLE 28 Global Bronchodilators Market by Region, 2022 - 2028, USD Million
  • TABLE 29 North America Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 30 North America Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 31 North America Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 32 North America Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 33 North America Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 34 North America Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 35 North America Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 36 North America Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 37 North America Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 38 North America Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 39 North America Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 40 North America Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 41 North America Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 42 North America Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 43 North America Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 44 North America Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 45 North America Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 46 North America Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 47 North America Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 48 North America Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 49 North America Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 50 North America Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 51 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 52 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 53 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 54 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 55 North America Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 56 North America Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 57 US Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 58 US Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 59 US Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 60 US Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 61 US Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 62 US Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 63 US Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 64 US Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 65 Canada Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 66 Canada Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 67 Canada Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 68 Canada Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 69 Canada Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 70 Canada Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 71 Canada Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 72 Canada Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 73 Mexico Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 74 Mexico Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 75 Mexico Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 76 Mexico Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 77 Mexico Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 78 Mexico Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 79 Mexico Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 80 Mexico Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 81 Rest of North America Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 82 Rest of North America Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 83 Rest of North America Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 84 Rest of North America Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 85 Rest of North America Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 86 Rest of North America Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 87 Rest of North America Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 88 Rest of North America Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 89 Europe Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 90 Europe Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 91 Europe Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 92 Europe Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 93 Europe Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 94 Europe Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 95 Europe Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 96 Europe Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 97 Europe Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 98 Europe Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 99 Europe Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 100 Europe Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 101 Europe Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 102 Europe Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 103 Europe Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 104 Europe Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 105 Europe Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 106 Europe Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 107 Europe Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 108 Europe Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 109 Europe Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 110 Europe Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 111 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 112 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 113 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 114 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 115 Europe Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 116 Europe Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 117 Germany Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 118 Germany Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 119 Germany Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 120 Germany Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 121 Germany Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 122 Germany Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 123 Germany Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 124 Germany Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 125 UK Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 126 UK Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 127 UK Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 128 UK Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 129 UK Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 130 UK Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 131 UK Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 132 UK Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 133 France Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 134 France Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 135 France Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 136 France Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 137 France Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 138 France Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 139 France Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 140 France Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 141 Russia Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 142 Russia Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 143 Russia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 144 Russia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 145 Russia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 146 Russia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 147 Russia Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 148 Russia Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 149 Spain Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 150 Spain Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 151 Spain Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 152 Spain Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 153 Spain Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 154 Spain Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 155 Spain Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 156 Spain Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 157 Italy Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 158 Italy Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 159 Italy Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 160 Italy Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 161 Italy Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 162 Italy Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 163 Italy Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 164 Italy Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 165 Rest of Europe Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 166 Rest of Europe Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 167 Rest of Europe Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 168 Rest of Europe Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 169 Rest of Europe Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 170 Rest of Europe Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 171 Rest of Europe Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 172 Rest of Europe Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 173 Asia Pacific Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 174 Asia Pacific Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 175 Asia Pacific Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 176 Asia Pacific Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 177 Asia Pacific Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 178 Asia Pacific Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 179 Asia Pacific Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 180 Asia Pacific Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 181 Asia Pacific Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 182 Asia Pacific Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 183 Asia Pacific Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 184 Asia Pacific Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 185 Asia Pacific Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 186 Asia Pacific Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 187 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 188 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 189 Asia Pacific Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 190 Asia Pacific Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 191 Asia Pacific Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 192 Asia Pacific Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 193 Asia Pacific Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 194 Asia Pacific Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 195 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 196 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 197 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 198 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 199 Asia Pacific Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 200 Asia Pacific Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 201 China Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 202 China Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 203 China Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 204 China Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 205 China Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 206 China Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 207 China Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 208 China Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 209 Japan Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 210 Japan Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 211 Japan Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 212 Japan Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 213 Japan Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 214 Japan Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 215 Japan Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 216 Japan Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 217 India Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 218 India Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 219 India Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 220 India Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 221 India Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 222 India Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 223 India Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 224 India Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 225 South Korea Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 226 South Korea Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 227 South Korea Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 228 South Korea Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 229 South Korea Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 230 South Korea Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 231 South Korea Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 232 South Korea Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 233 Singapore Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 234 Singapore Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 235 Singapore Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 236 Singapore Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 237 Singapore Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 238 Singapore Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 239 Singapore Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 240 Singapore Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 241 Malaysia Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 242 Malaysia Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 243 Malaysia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 244 Malaysia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 245 Malaysia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 246 Malaysia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 247 Malaysia Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 248 Malaysia Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 249 Rest of Asia Pacific Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 250 Rest of Asia Pacific Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 251 Rest of Asia Pacific Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 252 Rest of Asia Pacific Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 253 Rest of Asia Pacific Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 254 Rest of Asia Pacific Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 255 Rest of Asia Pacific Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 256 Rest of Asia Pacific Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 257 LAMEA Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 258 LAMEA Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 259 LAMEA Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 260 LAMEA Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 261 LAMEA Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 262 LAMEA Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 263 LAMEA Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 264 LAMEA Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 265 LAMEA Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 266 LAMEA Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 267 LAMEA Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 268 LAMEA Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 269 LAMEA Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 270 LAMEA Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 271 LAMEA Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 272 LAMEA Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 273 LAMEA Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 274 LAMEA Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 275 LAMEA Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 276 LAMEA Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 277 LAMEA Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 278 LAMEA Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 279 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 280 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 281 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 282 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 283 LAMEA Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 284 LAMEA Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 285 Brazil Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 286 Brazil Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 287 Brazil Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 288 Brazil Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 289 Brazil Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 290 Brazil Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 291 Brazil Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 292 Brazil Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 293 Argentina Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 294 Argentina Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 295 Argentina Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 296 Argentina Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 297 Argentina Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 298 Argentina Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 299 Argentina Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 300 Argentina Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 301 UAE Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 302 UAE Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 303 UAE Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 304 UAE Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 305 UAE Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 306 UAE Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 307 UAE Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 308 UAE Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 309 Saudi Arabia Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 310 Saudi Arabia Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 311 Saudi Arabia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 312 Saudi Arabia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 313 Saudi Arabia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 314 Saudi Arabia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 315 Saudi Arabia Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 316 Saudi Arabia Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 317 South Africa Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 318 South Africa Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 319 South Africa Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 320 South Africa Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 321 South Africa Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 322 South Africa Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 323 South Africa Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 324 South Africa Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 325 Nigeria Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 326 Nigeria Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 327 Nigeria Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 328 Nigeria Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 329 Nigeria Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 330 Nigeria Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 331 Nigeria Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 332 Nigeria Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 333 Rest of LAMEA Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 334 Rest of LAMEA Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 335 Rest of LAMEA Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 336 Rest of LAMEA Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 337 Rest of LAMEA Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 338 Rest of LAMEA Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 339 Rest of LAMEA Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 340 Rest of LAMEA Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 341 Key Information - Glenmark Pharmaceuticals Limited
  • TABLE 342 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 343 Key Information - GlaxoSmithKline PLC
  • TABLE 344 KEY INFORMATION - AstraZeneca PLC
  • TABLE 345 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 346 Key Information - Cipla Limited
  • TABLE 347 key information - Viatris, Inc.
  • TABLE 348 Key Information - Novartis AG
  • TABLE 349 Key Information - Boehringer Ingelheim International GmbH
  • TABLE 350 Key Information - Sun Pharmaceutical Industries Ltd.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Bronchodilators Market share by Drug Class, 2021
  • FIG 3 Global Bronchodilators Market share by Drug Class, 2028
  • FIG 4 Global Bronchodilators Market by Drug Class, 2018 - 2028, USD Million
  • FIG 5 Global Bronchodilators Market share by Route of Administration, 2021
  • FIG 6 Global Bronchodilators Market share by Route of Administration, 2028
  • FIG 7 Global Bronchodilators Market by Route of Administration, 2018 - 2028, USD Million
  • FIG 8 Global Bronchodilators Market share by Disease, 2021
  • FIG 9 Global Bronchodilators Market share by Disease, 2028
  • FIG 10 Global Bronchodilators Market by Disease, 2018 - 2028, USD Million
  • FIG 11 Global Bronchodilators Market share by Region, 2021
  • FIG 12 Global Bronchodilators Market share by Region, 2028
  • FIG 13 Global Bronchodilators Market by Region, 2018 - 2028, USD Million